Revier Therapeutics
revier.bio
Biotechnology
Revier Therapeutics focuses on developing therapies targeting class IIa histone deacetylases (HDACs) for cardiometabolic diseases. Their innovative approach aims to provide new treatment options for conditions such as heart failure and atherosclerotic cardiovascular disease.
Founded
2022
Total Funding
$1M+
Total Rounds
1
First Raise
Aug 25, 2026
Latest Raise
Aug 25, 2026
Get notified when Revier Therapeutics and companies like it raise
New funding rounds in your inbox every week 路 No noise, all Signal.
Organization Chart
Founders and leadership hierarchy for this company.
Contact details require Sales or Enterprise
Open Roles
Loading open roles...
All Funding Rounds
| Date | Deal Type | Amount | Lead Investor |
|---|---|---|---|
| 8/25/2026 | |||
Company Performance Metrics
Premium Feature
Upgrade to Premium to view Capital Momentum Score and performance metrics
Revier Therapeutics 路 Never miss the next round
Who's raising next?
New funding rounds in your inbox every week 路 Free